Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 517-524

  Horiguchi, Jun ^a,g   Oyama, Tetsunari ^a   Koibuchi, Yukio ^a   Yokoe, Takao ^b   Takata, Daisuke ^c   Ikeda, Fumihiro ^d   Nagaoka, Hiroshi ^e   Rokutanda, Nana ^a   Nagaoka, Rin ^a   Ishikawa, Yuko ^a   Odawara, Hiroki ^a   Kikuchi, Mami ^a   Sato, Ayako ^a   Iinio, Yuichi ^f   Takeyoshi, Izumi ^a  

^a GUNMA UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c Shibukawa General Hospital   (Japan)

^d National Hospital Organization   (Japan)

^e MAEBASHI RED CROSS HOSPITAL   (Japan)

^f Japanese Red Cross Society   (Japan)

^g GUNMA UNIVERSITY   (Japan)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Paclitaxel; Pathological response; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; ALLERGY; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUSHING; FOLLOW UP; GRANULOCYTOPENIA; HISTOPATHOLOGY; HUMAN; LARYNGITIS; LEUKOPENIA; LIVER DYSFUNCTION; LOADING DRUG DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; PACLITAXEL; RECEPTOR, ERBB-2;

EID: 61449226594     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Eniu A, Palmieri FM and Perez EA: Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10: 665-685, 2005.
2. Sledge GW, Neuberg D, Bernard P et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21: 588-592, 2003.
3. Parideans R, Biganzoli L, Bruning P et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 18: 724-733, 2000.
4. Buzdar AU, Singletary SE, Theriault RL et al: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17: 3412-3417, 1999.
5. Dittrich C, Jakesz R and Gnant M: Preoperative paclitaxel (TOL) in the first-line therapy of patients with breast cancer T3/4, N0-3, M0, followed by surgery, CMF±tamoxifen and radiotherapy: Phase II trial. Proc Am Soc Clin Oncol 16: 166a (Abstr 581), 1997.
6. Volm M, Forment S, Symmans F et al: Neo-adjuvant paclitaxel for locally advanced breast cancer (LABC): Preliminary results. Proc Am Soc Clin Oncol 17: 181 (Abstr 695), 1998.
7. Slamon DJ, Godolphin W, Jones LA et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
8. Sachelarie I, Grossbard ML, Chadha M et al: Primary systemic therapy of breast cancer. The Oncologist 11: 574-589, 2006.
9. Buzdar AU, Ibrahim NK, Francis D et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676-3685, 2005.
10. Slamon DJ, Leyland-Jones B, Shak S et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344: 783-792, 2001.
11. Robert NJ, Vogel CL, Henderson IC et al: The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol 31: 106-146, 2004.
12. Bullock K and Blackwell K: Clinical efficacy of taxane-trastuzumab combination regimen for HER-2-positive metastatic breast cancer. Oncologist 13: 515-525, 2008.
13. Seidman AD, Berry D, Cirrincione C et al: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26: 1642-1649, 2008.
14. Coudert BP, Largillier R, Arnould L et al: Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor-2 overexpressing stage II or III breast cancer: Results of the GETN (A)-1 trial. J Clin Oncol 25: 2678-2684, 2007.
15. Limentani SA, Brufsky AM, Erban JK et al: Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor 2-overexpressing locally advanced breast cancer. J Clin Oncol 25: 1232-1238, 2007.
16. Hannemann J, Oosterkamp HM, Bosch CAJ et al: Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 23: 3331-3342, 2005.
17. Gralow JR, Burstein HJ, Wood W et al: Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issue in operable disease. J Clin Oncol 26: 814-819, 2008.
18. Miyoshi Y, Kurosumi M, Kurebayashi J et al: Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers. J Cancer Res Clin Oncol 134: 561-567, 2008.
19. Colleoni M, Viale G, Zahrieh D et al: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10: 6622-6628, 2004.
20. Bonadonna G, Valagussa P, Zucali R et al: Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 45: 227-243, 1995.
21. Mazouni C, Kau SW, Frye D et al: Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 18: 874-880, 2007.
22. Fisher B, Bryant J, Wolmark N et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998.
23. Kuerer HM, Newman LA, Smith TL et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469, 1999.
24. Bonadonna G, Valagussa P, Brambilla C et al: Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93-100, 1998.
25. Tewari M, Krishnamurthy A and Shukla HS: Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol (in press).
26. Penault-Llorca F, Abrial C, Mouret-Reynier MA et al: Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer. The Oncologist 12: 390-396, 2007.
27. Rouzier R, Perou CM, Symmans WF et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685, 2005.
28. Buzdar AU, Valero V, Ibrahim NK et al: Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13: 228-233, 2007.
29. von Minckwitz G, Blohmer J, Vogel P et al: In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the Gepar-TRIO pilot study. Ann Oncol 16: 56-63, 2005.
30. von Minckwitz G, Kümmel S, Vogel P et al: Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 100: 552-562, 2008.
31. Smith IC, Heys SD, Hutcheon AW et al: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-1466, 2002.
32. Fenton M, Ries L, Strenger RS et al: Frequent pathologic complete responses seen with neoadjuvant q4week carboplatin and weekly paclitaxel ±weekly trastuzumab in resectable and locally advanced breast cancer: a Brown University Oncology Group (BrUOG) study. Breast Cancer Res Treat 94(Suppl 1): 5054, 2005.